Sign up to save your podcasts
Or
Share Johnson & Johnson News Daily
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Johnson & Johnson News Daily
Johnson & Johnson News Daily episodes
- JNJ Stock Near 52-Week High as Analysts Stay Bullish on Pipeline Growth# Johnson & Johnson (JNJ) Stock Analysis: Trading Near 52-Week High with Positive Analyst Outlook | March 2026 UpdateDive into the latest **Johnson & Johnson stock (JNJ) analysis** for March 2026. In this episode, we cover JNJ's trading performance, closing at $243.22 on March 16, 2026, near its 52-week high of $251.71 with a massive $582 billion market cap.**Key topics include:**- Recent **insider trading activity** including Executive VP Vanessa Broadhurst's share sale- **Institutional ownership** at 69.55% with Norges Bank's $4.88 billion position- Breakthrough **Erda-iDRS clinical trial results** for bladder cancer treatment- **Analyst upgrades** from Bank of America ($253), HSBC ($265), and others- **Consensus Moderate Buy rating** with average price target of $235.91- JNJ's continued **Dividend King status** with quarterly dividend paymentPerfect for investors tracking **pharmaceutical stocks**, **dividend aristocrats**, and **healthcare sector investments**. Get comprehensive insights on one of the world's leading healthcare companies and its stock market performance.Subscribe for regular stock market updates and financial analysis.*A Quiet Please Production | Visit quietplease.ai for more investment podcasts*---**Tags:** #JohnsonAndJohnson #JNJStock #StockMarket #DividendStocks #HealthcareStocks #InvestmentPodcast #StockAnalysis #MarketNewsFor more http://www.quietplease.aiStock up on these dealshttps://amzn.to/3QFpYIXThis content was created in partnership and with the help of Artificial Intelligence AI.3 min
- JNJ Stock Holds Steady: Defensive Play Amid Market Volatility and Geopolitical Uncertainty# Johnson & Johnson (JNJ) Stock Analysis: March 2026 Price Forecast & Analyst Outlook | Stock Market PodcastDiscover the latest Johnson & Johnson (JNJ) stock analysis for March 2026 in this comprehensive podcast episode. Trading at $241.52 as of March 16, 2026, JNJ stock demonstrates defensive strength amid market volatility.**Key highlights covered:**- Current JNJ stock price and trading range ($241-$245)- Short-term price forecasts: potential rise to $249.32 by Q1 end- Analyst upgrades: Daiwa Securities raises price target to $237 with outperform rating- Long-term projections reaching $270 by late March 2026- Revenue target: $100 billion for fiscal year 2026- Technical analysis showing medium volatility at 2.01%Learn why Johnson & Johnson remains a stable performer during market uncertainties, driven by strong operations across pharmaceuticals, medical devices, and consumer health divisions. Perfect for investors seeking defensive stocks and healthcare sector insights.**Episode Topics:** JNJ stock forecast 2026, Johnson & Johnson analyst ratings, pharmaceutical stock analysis, defensive stocks, healthcare sector investing, stock price predictionsA Quiet Please Studios production - Subscribe for daily stock market updates and investment insights.---*Duration: [Insert time] | Release Date: March 2026 | Category: Business & Finance, Investing, Stock Market Analysis*For more http://www.quietplease.aiStock up on these dealshttps://amzn.to/3QFpYIXThis content was created in partnership and with the help of Artificial Intelligence AI.3 min
- Johnson and Johnson Stock Shows Resilience With Bullish Momentum Ahead# Johnson & Johnson (JNJ) Stock Analysis: March 2026 Trading Update & Price Forecast | Podcast Episode DescriptionDive into the latest **Johnson & Johnson stock (JNJ) analysis** as of March 13, 2026, with comprehensive market insights and price predictions. Trading at $242.04, JNJ demonstrates **strong year-to-date performance** with gains of 16.7% and resilient short-term momentum up 7.27% over two weeks.This episode covers:- **Current JNJ stock price** and trading volume analysis showing 6M shares traded- **Price forecast** ranging from $242.99 to $257.53 for March 2026- **Analyst ratings**: Consensus Moderate Buy with Morgan Stanley's $262 price target- **Institutional trading activity** including recent moves by Bristol John W and ProShares- **Market sentiment indicators** with Fear & Greed Index at 39 (neutral)- **Dividend information**: $1.30 per share quarterly distribution- Short interest metrics and technical analysis including 50-day SMA performancePerfect for investors seeking **JNJ stock predictions**, pharmaceutical sector insights, and blue-chip dividend stock analysis. Stay informed on Johnson & Johnson's market position and trading opportunities.**Subscribe** for regular stock market updates and investment analysis. A Quiet Please Studios production - visit quietplease.ai for more financial podcasts.*Keywords: Johnson & Johnson stock, JNJ stock price, JNJ forecast 2026, dividend stocks, pharmaceutical stocks, stock analysis podcast*For more http://www.quietplease.aiStock up on these dealshttps://amzn.to/3QFpYIXThis content was created in partnership and with the help of Artificial Intelligence AI.3 min
- JNJ Stock Surges on Oncology Wins Despite Lower Trading Volume# Johnson & Johnson Stock Analysis: JNJ Trading Update, FDA Approval & Analyst Price Targets | Healthcare Stock Podcast**Episode Description:**Dive into the latest Johnson & Johnson (JNJ) stock analysis as shares trade at $242.79, down 0.38% from the previous close. This comprehensive episode covers JNJ's impressive performance with 18% year-to-date gains and 57% growth over the past year, reaching a massive $587 billion market cap.Discover key catalysts driving the healthcare giant, including FDA approval of TECVAYLI plus DARZALEX FASPRO for multiple myeloma treatment, which strengthens Johnson & Johnson's oncology portfolio. Learn about the $65 million Tracleer antitrust settlement and what it means for investors.Get the latest analyst insights with Citigroup raising its price target to $274 (12.94% upside potential) and maintaining a buy rating. We break down consensus targets, ratings from TD Cowen and Goldman Sachs, plus notable changes in short interest (up 20.8%) and insider selling activity.With 5.3% operational growth projecting $94.2 billion in 2025 revenue, a 2.1% dividend yield, and strong performance against healthcare peers, discover whether JNJ stock deserves a place in your portfolio.**Keywords:** Johnson & Johnson stock, JNJ stock analysis, healthcare stocks, pharmaceutical stocks, FDA approval, analyst price targets, dividend stocks, stock market podcast, investment analysis*A Quiet Please Production | Subscribe for daily stock market insights*For more http://www.quietplease.aiStock up on these dealshttps://amzn.to/3QFpYIXThis content was created in partnership and with the help of Artificial Intelligence AI.4 min
- JNJ Holds Strong Near 52-Week High Amid Mixed Market Signals and Geopolitical Tensions# Johnson & Johnson Stock Analysis: JNJ Trading at $240.40 with Analyst Upgrades | March 2026 Market UpdateDiscover the latest **Johnson & Johnson (JNJ) stock analysis** as shares trade at $240.40 on March 10, 2026. This comprehensive podcast episode breaks down JNJ's current market position, featuring recent analyst upgrades from Wolfe Research and Daiwa Capital Markets.In this episode, we examine:- **JNJ stock price movement**: Up 0.32% with trading volume exceeding 7.1 million shares- **Analyst consensus and price targets**: 26 analysts project targets averaging $199-$237, with recent upgrades to "outperform" and "strong buy" ratings- **Dividend information**: $1.30 quarterly dividend with 0.636% yield- **Market context**: How rising oil prices ($119/barrel) amid Iran tensions may impact healthcare sector margins- **52-week performance**: Stock trading near its high of $248.56Whether you're a Johnson & Johnson shareholder, healthcare sector investor, or market analyst, this episode provides essential insights into JNJ's fundamentals and technical position. Data sourced from Tickeron, MarketBeat, StockAnalysis, and Johnson & Johnson investor relations.**Subscribe for daily stock market analysis and investment insights.***A Quiet Please Studios production | Visit quietplease.ai for more financial podcasts***Keywords**: Johnson & Johnson stock, JNJ stock analysis, healthcare stocks, dividend stocks, pharmaceutical stocks, stock market analysis 2026For more http://www.quietplease.aiStock up on these dealshttps://amzn.to/3QFpYIXThis content was created in partnership and with the help of Artificial Intelligence AI.3 min
- Johnson and Johnson Stock Analysis: Solid Uptrend with Bullish Analyst Sentiment# Johnson & Johnson (JNJ) Stock Analysis: Strong Momentum at $240+ with Bullish Analyst Targets | Market Update 2024Dive into the latest **Johnson & Johnson stock analysis** as JNJ shares trade above $240, showcasing impressive momentum in the pharmaceutical and healthcare sector. This comprehensive episode examines JNJ's recent performance, including its $579.75 billion market cap and solid Q1 earnings of $2.46 EPS on $24.28 billion revenue.Discover why 27 Wall Street analysts maintain a **"moderate buy" consensus** with an average price target of $234.87. We break down recent upgrades from major firms including **Citigroup's $250 target**, **Morgan Stanley's $262 overweight rating**, and **Argus's boost to $240**.Key highlights include:- JNJ's upward trend with 50-day MA at $228.36 and 200-day MA at $204.19- Attractive 47% dividend payout ratio for income investors- Strong institutional ownership at 69.55%- PE ratio of 21.77 indicating reasonable valuation- 52-week range analysis: $141.50 to $251.71Perfect for investors seeking **pharmaceutical stock insights**, **dividend investing strategies**, and **healthcare sector analysis**. Whether you're a long-term investor or active trader, this episode provides actionable market intelligence on one of healthcare's blue-chip leaders.Subscribe for regular **stock market updates** and **investment analysis**. A Quiet Please Studios production.#StockMarket #JNJ #JohnsonAndJohnson #Investing #MarketAnalysis #DividendStocks #Healthcare #PharmaceuticalsFor more http://www.quietplease.aiStock up on these dealshttps://amzn.to/3QFpYIXThis content was created in partnership and with the help of Artificial Intelligence AI.3 min
- JNJ Stock Dips to 239.65: Analyst Upgrades and FDA News Signal Buying Opportunity# Johnson & Johnson (JNJ) Stock Analysis: March 2025 Update | Price Targets, FDA Approvals & Investment Outlook**Meta Description:** Johnson & Johnson stock (JNJ) analysis for March 2025. Discover latest price targets from JPMorgan, HSBC, and other analysts, FDA fast-track approvals, dividend yield, and whether the recent dip to $239 presents a buying opportunity.---**Episode Description:**Dive into a comprehensive analysis of **Johnson & Johnson stock (JNJ)** following its recent market movements in early March 2025. This episode breaks down JNJ's performance as the stock dipped 2.3% to $239.65 despite trading above its closing price of $245.30.**Key topics covered:**📊 **Stock Performance Metrics**- 52-week trading range analysis ($141.50 - $251.71)- Market capitalization near $577 billion USD- Trading volume comparison: 9.37M shares vs. 9.03M average- Current dividend yield of 2.12%🎯 **Analyst Price Targets & Ratings**- JPMorgan Chase upgrades target to $250 (from $225)- HSBC raises to $265 with "Buy" rating- Leerink Partners and Wolfe Research updates- Consensus moderate buy rating at $234.87 average target💊 **Positive Catalysts**- New direct-to-consumer sales platform launch in the US- FDA fast-track designation for nipocalimab (Phase 3)- Strong Q4 earnings: $2.46 per share- Institutional buying from Vanguard Group⚠️ **Risk Factors**- Ongoing litigation concerns- Executive insider selling activity- Broader pharmaceutical sector weaknessIs the recent pullback to $239 a **strategic buying opportunity** for dividend investors? Get expert insights on JNJ's stability, growth prospects, and risk-reward profile in this essential stock market podcast episode.*A Quiet Please Studios Production | Subscribe for daily stock market analysis and investment insights***Keywords:** Johnson & Johnson stock, JNJ stock analysis, pharmaceutical stocks, dividend stocks 2025, FDA approvals, stock price targets, investment podcastFor more http://www.quietplease.aiStock up on these dealshttps://amzn.to/3QFpYIXThis content was created in partnership and with the help of Artificial Intelligence AI.3 min
- JNJ Stock Steady at $154.22: Analyst Optimism Meets Litigation Concerns# SEO-Friendly Podcast Episode Description## Johnson & Johnson Stock Analysis: March 5, 2026 Market Update | JNJ Trading at $154.22Dive into today's comprehensive analysis of **Johnson & Johnson (JNJ) stock performance** on March 5, 2026. In this episode, we cover JNJ's current trading price of $154.22 per share, representing a 0.3% increase and demonstrating steady investor confidence in this healthcare industry leader.**Key Topics Covered:**- Real-time JNJ stock price and trading volume analysis- Breaking news: Successful Phase 3 trial results for experimental rare lung disease treatment- Q4 2025 earnings beat with $22.5 billion revenue (5% YoY growth)- Latest analyst ratings from Goldman Sachs and Morgan Stanley- Price target updates and buy/hold recommendations- Dividend yield information (3.1%) and investment outlook**Market Insights:**Learn about JNJ's below-average trading volume of 4.8 million shares, Goldman Sachs' raised price target to $170, and why the stock remains attractive for income investors with its forward P/E ratio of 14.8.Perfect for investors, traders, and anyone interested in **pharmaceutical stocks**, **healthcare sector analysis**, **dividend investing**, and **blue-chip stock performance**.*Subscribe for daily stock market updates and financial news analysis.***#JohnsonAndJohnson #JNJStock #StockMarketAnalysis #PharmaceuticalStocks #DividendStocks #HealthcareInvesting #MarketUpdate #StockTrading**---*A Quiet Please Production | Visit quietplease.ai for more financial podcasts*For more http://www.quietplease.aiStock up on these dealshttps://amzn.to/3QFpYIXThis content was created in partnership and with the help of Artificial Intelligence AI.3 min
- JNJ Steady Climb: Healthcare Giant Rides Strong Earnings and Analyst Upgrades Into March# SEO-Friendly Podcast Episode Description**Johnson & Johnson (JNJ) Stock Analysis: March 2026 Market Update & Positive Phase 3 Trial Results**Discover the latest insights on Johnson & Johnson stock (NYSE: JNJ) trading at $154.22 per share as of March 4, 2026. In this comprehensive market analysis episode, we cover:📈 **Key Highlights:**- Current JNJ stock price showing 0.3% daily gain- Breakthrough Phase 3 trial results for inflammatory bowel disease treatment- Q4 2025 earnings beat with $22.47B revenue (up 6.5% YoY)- Bullish analyst ratings from Barclays ($175 target) and Oppenheimer ($170 target)💰 **Investment Fundamentals:**- Attractive 3.1% dividend yield- Undervalued forward P/E ratio of 15.2- Strong balance sheet with $30B+ in cash reserves- Manageable talc litigation settlements**Perfect for:** Healthcare investors, dividend seekers, pharmaceutical industry watchers, and anyone tracking blue-chip stock opportunities.**Episode Duration:** Quick market briefing formatStay informed on healthcare sector investments and JNJ stock performance. Subscribe for daily stock market updates and pharmaceutical industry news.*A Quiet Please Studios Production | Visit quietplease.ai for more financial podcast content*---**Tags:** #JohnsonAndJohnson #StockMarket #JNJStock #HealthcareInvesting #PharmaceuticalStocks #DividendStocks #MarketAnalysis #InvestingPodcastFor more http://www.quietplease.aiStock up on these dealshttps://amzn.to/3QFpYIXThis content was created in partnership and with the help of Artificial Intelligence AI.3 min
- Johnson and Johnson Stock Momentum: Strong Earnings and Cardiac Data Drive Analyst Optimism# Johnson & Johnson Stock Surges: Q4 2025 Earnings Beat & Breakthrough Cardiac Study Drive Momentum | JNJ Stock AnalysisJohnson & Johnson (JNJ) stock continues its impressive rally, trading near $243 with strong momentum following exceptional Q4 2025 earnings and breakthrough cardiac clinical trial results. In this episode, we break down the healthcare giant's recent performance, including its $24.6 billion quarterly revenue (up 9.1% YoY), 2026 guidance projecting $100 billion in sales, and the game-changing OMNY AF pilot study showing 90% freedom from atrial fibrillation.**Key Topics Covered:**- JNJ stock analysis and current trading levels ($243, market cap $586.79B)- Q4 2025 earnings breakdown and 2026 operational sales growth guidance (5.7-6.7%)- OMNY AF cardiac study results and implications for cardiology pipeline- Analyst upgrades: Morgan Stanley moves to Overweight, RBC raises price target to $255- Technical analysis: 52-week range, moving averages, and bullish signals- Valuation insights: Simply Wall St estimates 36.4% undervaluation- Trading volume patterns and market sentiment indicators**Analyst Price Targets:** Consensus between $233-$237, with high estimates reaching $265Whether you're a healthcare sector investor, dividend growth enthusiast, or looking for blue-chip pharmaceutical stock opportunities, this episode provides comprehensive analysis of Johnson & Johnson's recent catalysts and forward outlook for 2026.**#JohnsonAndJohnson #JNJStock #StockMarket #HealthcareStocks #EarningsAnalysis #PharmaceuticalStocks #InvestingPodcast #StockAnalysis #DividendStocks #CardiacResearch**For more http://www.quietplease.aiStock up on these dealshttps://amzn.to/3QFpYIXThis content was created in partnership and with the help of Artificial Intelligence AI.3 min
About Johnson & Johnson News Daily
From the publisher's feed
Stay informed with "Johnson & Johnson News Daily," the essential podcast for tracking JNJ stock and staying updated on all things Johnson & Johnson. Our daily episodes deliver the latest news, expert insights, and valuable information on company developments, market trends, and financial performance. Whether you're an investor, industry professional, or simply interested in one of the world's leading healthcare companies, tune in to stay ahead of the curve with "Johnson & Johnson News Daily."
For more info go to https://www.quietperiodplease.com
Check out these deals https://amzn.to/3zlo77e
Also check out
https://podcasts.apple.com/us/channel/what-to-do-in-city-guides/id6615091666
This content was created in partnership and with the help of Artificial Intelligence AI.